Diabetes trial success

Original article by Tim Binsted
The Australian Financial Review – Page: 22 : 9-Jun-15

Listed biotechnology group Mesoblast has reported encouraging results from the phase two trial of a treatment for diabetic nephropathy. CEO Silviu Itescu says nearly two million people had the diabetes-related kidney disease in 2013. The clinical trial found that the stem cell-based treatment showed that participants had improved kidney function and experienced no adverse side-effects.

CORPORATES
MESOBLAST LIMITED – ASX MSB, AMERICAN DIABETES ASSOCIATION, CELGENE INCORPORATED, SIRTEX MEDICAL LIMITED – ASX SRX

Cochlear looks to new CEO for kick-start

Original article by Tim Binsted
The Australian Financial Review – Page: 15 & 20 : 27-May-15

Australian-listed Cochlear has advised that the head of its North American division, Chris Smith, will succeed CEO Chris Roberts in September 2015. Roberts has been CEO since 2004, and Cochlear has indicated that it wants to place more emphasis on lifting sales and revenue under Smith. He will join Cochlear in the role of deputy CEO on 1 July. Cochlear shares closed 1.4 per cent higher at $A88.66 on 26 May.

CORPORATES
COCHLEAR LIMITED – ASX COH, RESMED INCORPORATED – ASX RMD, MACQUARIE GROUP LIMITED – ASX MQG, NUCLEUS GROUP, SEEK LIMITED – ASX SEK, ATLASSIAN SOFTWARE SYSTEMS PTY LTD, AUSTRALIAN MANUFACTURING WORKERS’ UNION

ResMed falls 18pc as trial boosts patients’ risk of dying

Original article by Jessica Gardner
The Australian Financial Review – Page: 15 & 20 : 15-May-15

Wilson HTM has changed its recommendation on ResMed from "buy" to "sell" after clinical trials of a sleep apnoea device showed that patients with a heart condition were at greater risk of death when using it. The results of the clinical trial prompted ResMed’s Australian-listed shares to close $A1.52 lower at $A6.73 on 14 May 2015. ResMed notes that the ventilation machine used in the clinical trial accounted for just seven per cent of its revenue in the last financial year.

CORPORATES
RESMED INCORPORATED – ASX RMD, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, CREDIT SUISSE (AUSTRALIA) LIMITED, DEUTSCHE BANK AG, UBS HOLDINGS PTY LTD

Mesoblast takes US cancer giant Celgene as latest partner

Original article by Jessica Gardner
The Australian Financial Review – Page: 17 : 14-Apr-15

Shares in Mesoblast rose by 24 per cent to $A3.99 on 13 April 2015, after US-based Celgene acquired a stake of around 4.5 per cent in the listed biotechnology group. Celgene paid $A58.5m for 15.3 million shares in Mesoblast, which specialises in the development of stem cell treatments for a range of medical conditions. Celgene will also have first right of refusal to license some of Mesoblast’s products

CORPORATES
MESOBLAST LIMITED – ASX MSB, CELGENE INCORPORATED, TEVA PHARMACEUTICAL INDUSTRIES LIMITED, LODGE PARTNERS PTY LTD

Sirtex sheds $1b after cancer therapy trial disappoints

Original article by Jessica Gardner
The Australian Financial Review – Page: 11 & 17 : 18-Mar-15

Sirtex Medical’s shares closed 55 per cent lower at $A17.53 on 17 March 2015, after the group released the results of a seven-year clinical trial of its SIR-Spheres treatment for liver cancer. The trial found that the treatment does not offer much improvement compared with traditional treatments such as chemotherapy. However, Sirtex intends to make more extensive data on the clinical trial available in May

CORPORATES
SIRTEX MEDICAL LIMITED – ASX SRX, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, MESOBLAST LIMITED – ASX MSB, CSL LIMITED – ASX CSL, ONCOSIL MEDICAL LIMITED – ASX OSL, MORGANS FINANCIAL LIMITED, BLOOMFIELD COLLIERIES, UBS HOLDINGS PTY LTD, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, AUSTRALIAN ETHICAL INVESTMENT LIMITED – ASX AEF

CSL could be the next to reach the dizzy heights of $100 a share

Original article by Misa Han
The Australian Financial Review – Page: 22 : 6-Mar-15

Shares in CSL are trading at $A92.18, and there is speculation that the stock will breach the $A100 level. Goldman Sachs is among the CSL bulls, with a share price target of $A107, although the average 12-month share price target of analysts polled by Bloomberg is just $A90.23. CSL shares rose above $A100 in September 2007, although the group then opted for a stock split. Wilson HTM Investment Group says it could do so again if the stock reaches $A100

CORPORATES
CSL LIMITED – ASX CSL, GOLDMAN SACHS AND PARTNERS AUSTRALIA PTY LTD, BLOOMBERG LP, WILSON HTM INVESTMENT GROUP LIMITED – ASX WIG, RIO TINTO LIMITED – ASX RIO, COMMONWEALTH BANK OF AUSTRALIA – ASX CBA, DEUTSCHE BANK AG, SONIC HEALTHCARE LIMITED – ASX SHL, RESMED INCORPORATED – ASX RMD, HEALTHSCOPE LIMITED – ASX HSO, ANSELL LIMITED – ASX ANN, NIB HOLDINGS LIMITED – ASX NHF, RAMSAY HEALTH CARE LIMITED – ASX RHC, COCHLEAR LIMITED – ASX COH, MEDIBANK PRIVATE LIMITED – ASX MPL, STANDARD AND POOR’S ASX 200 INDEX

Apple’s pick of the crop as reality bites for other heroes

Original article by Philip Baker
The Australian Financial Review – Page: 30 : 12-Feb-15

The market capitalisation of Apple rose to $US711bn on 11 February 2015, and the IT giant may be on track to become the first company to achieve a market value of $US1trn. Apple shares have risen by more than 50,600 per cent since its IPO in 1980. Meanwhile, shares in Australian-listed Commonwealth Bank and CSL retreated on 11 February, although both remain close to record highs and are candidates to reach $A100 per share

CORPORATES
COMMONWEALTH BANK OF AUSTRALIA – ASX CBA, CSL LIMITED – ASX CSL, APPLE INCORPORATED, EXXONMOBIL CORPORATION, GOOGLE INCORPORATED, MICROSOFT CORPORATION, WESTPAC BANKING CORPORATION – ASX WBC, UNIVERSITY OF MELBOURNE. INSTITUTE OF APPLIED ECONOMIC AND SOCIAL RESEARCH

Gloomy growth forecast bloodies bullish CSL investors

Original article by Jessica Gardner
The Australian Financial Review – Page: 21 & 26 : 12-Feb-15

Australian-listed CSL has posted a 2014-15 interim net profit of $US692.2m, which is 7.2 per cent higher than previously. Revenue for the half-year was $A2.8bn, an increase of 5.6 per cent. CSL has advised that its full-year profit will be below previous guidance, although it is still on track to deliver a double-digit increase in earning. Shareholders will receive a half-year dividend of $US0.58 per share

CORPORATES
CSL LIMITED – ASX CSL, UBS HOLDINGS PTY LTD, PHILO CAPITAL ADVISERS PTY LTD, UNITED STATES. FOOD AND DRUG ADMINISTRATION, AURORA FUNDS MANAGEMENT LIMITED, STANDARD AND POOR’S ASX 200 INDEX

Cochlear amplifies profit result

Original article by Jessica Gardner
The Australian Financial Review – Page: 15 & 20 : 11-Feb-15

Australian-listed Cochlear has posted a 2014-15 interim underlying net profit of $A71.4m, which is 94 per cent higher than previously. The group’s statutory net profit was 240 per cent higher, while revenue was up 18 per cent at $A438.3m. Shareholders will receive a half-year dividend of $A0.90 per share. Cochlear shares fell by $A0.84 on 10 February 2015, closing at $A86.76

CORPORATES
COCHLEAR LIMITED – ASX COH, UBS HOLDINGS PTY LTD, AUSTRALIAN ETHICAL INVESTMENT LIMITED – ASX AEF, STANDARD AND POOR’S ASX 200 INDEX

CBA, CSL and Macquarie Group on track for $100 shares

Original article by Simon Evans
The Australian Financial Review – Page: 22 : 22-Jan-15

Shares in CSL and the Commonwealth Bank are currently trading at about $A84. While they have recently retreated from 12-months peaks, both stocks could potentially rise to $A100. CSL previously undertook a share split after its stock rose to $A100 in late 2007. Arnhem Investment Management’s George Clapham suggests that in many cases a demerger rather than a share split may generate more value for shareholders. Macquarie Group’s shares are currently trading above $A60, and the stock is also a potential candidate to breach $A100

CORPORATES
CSL LIMITED – ASX CSL, COMMONWEALTH BANK OF AUSTRALIA – ASX CBA, MACQUARIE GROUP LIMITED – ASX MQG, ARNHEM INVESTMENT MANAGEMENT PTY LTD, AMCOR LIMITED – ASX AMC, ORORA LIMITED – ASX ORA, BRAMBLES LIMITED – ASX BXB, RECALL HOLDINGS LIMITED – ASX REC, IRON MOUNTAIN INCORPORATED, ELDERS LIMITED – ASX ELD, BERKSHIRE HATHAWAY INCORPORATED